Skip to main content
Premium Trial:

Request an Annual Quote

Microchip Biotechnologies Reels in $18.1M in Financing

NEW YORK (GenomeWeb News) – Microchip Biotechnologies, which has developed a sample prep system for Sanger and next-generation sequencing, has received $18.1 million in series B financing from previous and new investors.

New investors include Domain Associates, Samsung Ventures, Western Technology Investment, and undisclosed individual investors; and previous investors Rona Syndicates and In-Q-Tel.

MBI, based in Pleasanton, Calif., is producing sample-processing systems based on its Apollo fluidics platform, which is designed for use in DNA and RNA sequencing, DNA-based forensics, and human identity testing.

The firm’s first offering is the Apollo 100 System, which it said can reduce the time, investment, and expense involved in sample preparation for Sanger cycle sequencing.

The financing will go toward marketing the Apollo 100 and developing the Apollo platform for next-generation sequencing applications.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more